Top Markets
Coin of the day
NuGenerex Immuno-Oncology, Inc. NuGenerex Immuno-Oncology, Inc.

NuGenerex Immuno-Oncology, Inc.

NUGX
Rangering i aksjer #41797
NuGenerex Immuno-Oncology, Inc. is an oncology firm committed to treating... NuGenerex Immuno-Oncology, Inc. is an oncology firm committed to treating cancer through the strategic modulation of the immune system. The company's development pipeline includes a range of immunotherapeutic products and vaccines. Notably, it is advancing AE37, a peptide immunotherapeutic vaccine, which is currently undergoing Phase II clinical studies for metastatic triple-negative breast cancer. Founded in 1993 and headquartered in Miramar, Florida, the entity was formerly named Antigen Express, Inc. NuGenerex Immuno-Oncology, Inc. operates as a subsidiary of Generex Biotechnology Corporation.
Aksjekurs
$0.0001
Sist synkronisert: 2023-05-22
Markedsverdi
$10.03K
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel NuGenerex Immuno-Oncology, Inc. (NUGX)

Kategori

P/B-forhold for NuGenerex Immuno-Oncology, Inc. (NUGX)
P/B-forhold per 2026 TTM: 0
Ifølge NuGenerex Immuno-Oncology, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/B-forhold på 0.
P/B-historikk for NuGenerex Immuno-Oncology, Inc. fra 2026 til 2026
P/B-forhold ved hvert års slutt
År P/B-forhold Endre
Ikke nok data for de angitte datoene.
P/B-forhold for lignende selskaper eller konkurrenter
Selskap P/B-forhold Forskjell i P/B-forhold Land
6.2613 -
US
6.3483 -
NL
- -
CH
3.634 -
BE
- -
KR